Link Details
- Metabolite
- HMDB0000122 (D-Glucose)
- DrugBank ID
- DB08907
- Drug Name
- Canagliflozin
- Effect
- Decrease
- Biospecimen
- Blood
- P-value
- Not Available
- Beta Estimator
- Not Available
- Percent Change
- Not Available
- Pearson Correlation Coefficient
- Not Available
- Comments
- Not Available
- Devineni D, Polidori D: Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. Clin Pharmacokinet. 2015 Oct;54(10):1027-41. doi: 10.1007/s40262-015-0285-z. [PubMed:26041408 ]
- Ghezzi C, Yu AS, Hirayama BA, Kepe V, Liu J, Scafoglio C, Powell DR, Huang SC, Satyamurthy N, Barrio JR, Wright EM: Dapagliflozin Binds Specifically to Sodium-Glucose Cotransporter 2 in the Proximal Renal Tubule. J Am Soc Nephrol. 2017 Mar;28(3):802-810. doi: 10.1681/ASN.2016050510. Epub 2016 Sep 12. [PubMed:27620988 ]
- Kheirandish M, Mahboobi H, Yazdanparast M, Kamal MA: Challenges related to glycemic control in type 2 Diabetes Mellitus patients. Curr Drug Metab. 2017 Jan 15. [PubMed:28093996 ]
- Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, Stein P: Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014 May;16(5):467-77. doi: 10.1111/dom.12273. Epub 2014 Mar 12. [PubMed:24528605 ]
- Inagaki N, Goda M, Yokota S, Maruyama N, Iijima H: Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study. Expert Opin Pharmacother. 2015;16(11):1577-91. doi: 10.1517/14656566.2015.1055250. Epub 2015 Jun 24. [PubMed:26104600 ]
- Nicolle LE, Capuano G, Fung A, Usiskin K: Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med. 2014 Jan;126(1):7-17. doi: 10.3810/pgm.2014.01.2720. [PubMed:24393747 ]